Sign In
Buy DAVA
Endava Earnings Calls
| Release date | May 21, 2026 |
| EPS estimate | $0.270 |
| EPS actual | $0.0700 |
| EPS Surprise | -74.07% |
| Revenue estimate | 242.788M |
| Revenue actual | 236.027M |
| Revenue Surprise | -2.78% |
| Release date | Feb 19, 2026 |
| EPS estimate | $0.210 |
| EPS actual | $0.210 |
| Revenue estimate | 241.82M |
| Revenue actual | 248.017M |
| Revenue Surprise | 2.56% |
| Release date | Nov 11, 2025 |
| EPS estimate | $0.245 |
| EPS actual | $0.200 |
| EPS Surprise | -18.30% |
| Revenue estimate | 236.676M |
| Revenue actual | 239.754M |
| Revenue Surprise | 1.30% |
| Release date | Sep 04, 2025 |
| EPS estimate | $0.320 |
| EPS actual | $0.320 |
| Revenue estimate | 186.412M |
| Revenue actual | 251.387M |
| Revenue Surprise | 34.86% |
Last 4 Quarters for Endava
Below you can see how DAVA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Sep 04, 2025 |
| Price on release | $9.97 |
| EPS estimate | $0.320 |
| EPS actual | $0.320 |
| Date | Price |
|---|---|
| Aug 28, 2025 | $14.67 |
| Aug 29, 2025 | $14.68 |
| Sep 02, 2025 | $14.34 |
| Sep 03, 2025 | $14.38 |
| Sep 04, 2025 | $9.97 |
| Sep 05, 2025 | $10.18 |
| Sep 08, 2025 | $10.03 |
| Sep 09, 2025 | $9.93 |
| Sep 10, 2025 | $9.40 |
| 4 days before | -32.04% |
| 4 days after | -5.72% |
| On release day | 2.11% |
| Change in period | -35.92% |
| Release date | Nov 11, 2025 |
| Price on release | $6.95 |
| EPS estimate | $0.245 |
| EPS actual | $0.200 |
| EPS surprise | -18.30% |
| Date | Price |
|---|---|
| Nov 05, 2025 | $8.89 |
| Nov 06, 2025 | $8.90 |
| Nov 07, 2025 | $9.30 |
| Nov 10, 2025 | $9.43 |
| Nov 11, 2025 | $6.95 |
| Nov 12, 2025 | $7.34 |
| Nov 13, 2025 | $6.91 |
| Nov 14, 2025 | $6.56 |
| Nov 17, 2025 | $6.33 |
| 4 days before | -21.82% |
| 4 days after | -8.92% |
| On release day | 5.61% |
| Change in period | -28.80% |
| Release date | Feb 19, 2026 |
| Price on release | $5.03 |
| EPS estimate | $0.210 |
| EPS actual | $0.210 |
| Date | Price |
|---|---|
| Feb 12, 2026 | $5.01 |
| Feb 13, 2026 | $5.10 |
| Feb 17, 2026 | $5.09 |
| Feb 18, 2026 | $5.23 |
| Feb 19, 2026 | $5.03 |
| Feb 20, 2026 | $4.94 |
| Feb 23, 2026 | $4.56 |
| Feb 24, 2026 | $4.54 |
| Feb 25, 2026 | $4.75 |
| 4 days before | 0.399% |
| 4 days after | -5.57% |
| On release day | -1.79% |
| Change in period | -5.19% |
| Release date | May 21, 2026 |
| Price on release | $3.34 |
| EPS estimate | $0.270 |
| EPS actual | $0.0700 |
| EPS surprise | -74.07% |
| Date | Price |
|---|---|
| May 15, 2026 | $3.84 |
| May 18, 2026 | $4.00 |
| May 19, 2026 | $3.95 |
| May 20, 2026 | $4.00 |
| May 21, 2026 | $3.34 |
| May 22, 2026 | $3.33 |
| May 26, 2026 | $3.24 |
| May 27, 2026 | $3.30 |
| May 28, 2026 | $3.22 |
| 4 days before | -13.02% |
| 4 days after | -3.59% |
| On release day | -0.299% |
| Change in period | -16.15% |
Endava Earnings Call Transcript Summary of Q1 2026
Endava reported Q1 FY2026 revenue of £178.2m, down 8.6% year-over-year (down 7.3% constant currency). The quarter missed prior guidance primarily because of an unexpected client credit in the U.S. and lower-than-expected conversion of non-large-pipeline opportunities. Adjusted profit before tax fell to £9.9m (margin 5.5%) and adjusted diluted EPS was £0.05. Cash generation improved (adjusted free cash flow £9.2m) and buybacks continue (ADS repurchases of $115.9m year-to-date, with remaining authorization). Management highlighted a strategic shift toward AI-native delivery (branded Dava Flow) and larger outcome-based, multiyear deals—illustrated by a newly signed up-to-$100m, five-year payments engagement that is mostly net-new revenue. Endava is investing heavily in AI talent (DARVAX Academy hires) and partnerships (OpenAI, Google Cloud, Salesforce) while acknowledging short-term margin/headcount friction as they accelerate the move from time-and-materials to outcome-based models. Guidance: Q2 revenue £179m–£182m (constant-currency decline 8–7% y/y) and adjusted diluted EPS £0.15–£0.17; full-year revenue guidance £735m–£752m (constant-currency decline 4.5–2.5% y/y) and adjusted diluted EPS £0.80–£0.88. Management expects recovery in H2 driven by signed large strategic deals, but has taken a more conservative conversion assumption for non-large deals.
